Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RAB9A | P51151 | 5/20 | 0.49 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.49 |
| ▸ | NPC1 | O15118 | 3/20 | 0.49 |
| ▸ | MAPT | P10636 | 1/20 | 0.49 |
| ▸ | AHR | P35869 | 1/20 | 0.49 |
| ▸ | MEN1 | O00255 | 3/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.47 |
| ▸ | DHODH | Q02127 | 1/20 | 0.47 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.44 |
| ▸ | P2RY1 | P47900 | 1/20 | 0.43 |
| ▸ | LRRK2 | Q5S007 | 2/20 | 0.41 |
| ▸ | L3MBTL1 | Q9Y468 | 3/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.39 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.39 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.39 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.39 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.39 |
| ▸ | KDR | P35968 | 3/20 | 0.37 |
| ▸ | LCK | P06239 | 2/20 | 0.37 |
| ▸ | BRAF | P15056 | 2/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15038511 | 0.95 | RAB9A (0.51) | RAB9ASMN1; SMN2NPC1MAPTAHR | |
| SCHEMBL15215726 | 0.84 | SMN1; SMN2 (0.44) | RAB9ASMN1; SMN2NPC1MAPTAHR | |
| SCHEMBL10047661 | 0.79 | RAB9A (0.48) | RAB9ASMN1; SMN2NPC1MAPTAHR | |
| SCHEMBL9469335 | 0.75 | RAB9A (0.60) | RAB9ASMN1; SMN2NPC1MAPTAHR | |
| SCHEMBL9838484 | 0.73 | RAB9A (0.54) | RAB9ASMN1; SMN2NPC1MAPTAHR | |
| SCHEMBL28076978 | 0.71 | MEN1 (0.82) | RAB9ASMN1; SMN2NPC1MEN1KMT2A | |
| SCHEMBL17307686 | 0.69 | DHODH (0.53) | RAB9ASMN1; SMN2NPC1MAPTAHR | |
| SCHEMBL18836778 | 0.69 | MEN1 (0.35) | RAB9ANPC1MEN1KMT2ACYP19A1 | |
| SCHEMBL10047675 | 0.69 | RAB9A (0.41) | RAB9ASMN1; SMN2NPC1MAPTAHR | |
| SCHEMBL11643488 | 0.69 | RAB9A (0.60) | RAB9ASMN1; SMN2NPC1MAPTAHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9212130-B2 | Heterocyclic derivative and pharmaceutical composition comprising the same | SHIONOGI & CO., LTD. (JP) | 2015-12-15 | — | — | US | disclosed |
| US-20130225596-A1 | NOVEL HETEROCYCLIC DERIVATIVE AND PHARMACEUTICAL COMPOSITION COMPRISING THE SAME (AS AMENDED) | SHIONOGI & CO., LTD. (JP) | 2013-08-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130225596-A1 | NOVEL HETEROCYCLIC DERIVATIVE AND PHARMACEUTICAL COMPOSITION COMPRISING THE SAME (AS AMENDED) | P2RX3, P2RX6, P2RX2 | RAB9A 3838/4885SMN1; SMN2 4299/4885NPC1 2254/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.